NCT03198884View on ClinicalTrials.gov

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

April 18, 2018

Study Completion Date

May 1, 2018

Conditions

HIV-1-infection

Interventions

DRUG

Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Southern Illinois Healthcare Foundation

OTHER

NCT03198884 - A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir | Biotech Hunter | Biotech Hunter